[Ad hoc announcement pursuant to Art. 53 LR] Roche ’s Columvi meets primary endpoint of overall survival in people with relapsed or refractory diffuse large B-cell lymphoma in Phase III STARGLO study
Columvi, in combination with chemotherapy, demonstrated a statistically significant improvement in overall survival for people with relapsed or refractory diffuse large B-cell lymphomaData from the STARGLO study will be submitted to health authorities and presented at an upcoming medical meetingBasel, 15 April 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the Phase III STARGLO study met its primary endpoint of overall survival. The study demonstrated that people with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), who have received at least one prior line of therapy and are not candidates fo...
Source: Roche Investor Update - April 15, 2024 Category: Pharmaceuticals Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche ’s Columvi meets primary endpoint of overall survival in people with relapsed or refractory diffuse large B-cell lymphoma in Phase III STARGLO study
Columvi, in combination with chemotherapy, demonstrated a statistically significant improvement in overall survival for people with relapsed or refractory diffuse large B-cell lymphomaData from the STARGLO study will be submitted to health authorities and presented at an upcoming medical meetingBasel, 15 April 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the Phase III STARGLO study met its primary endpoint of overall survival. The study demonstrated that people with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), who have received at least one prior line of therapy and are not candidates fo...
Source: Roche Media News - April 15, 2024 Category: Pharmaceuticals Source Type: news
My 'morning sickness' ended up being cancer: Mother-to-be, 24, is diagnosed at five months pregnant after glossing over 'weird' nausea and golf ball-sized lump in neck
Caitlin McAlinden, 24, put her cancer symptoms - including a golf ball-sized lump on her neck, nausea and fatigue - down to morning sickness. She was later diagnosed with
Hodgkin lymphoma. (Source: the Mail online | Health)
Source: the Mail online | Health - April 11, 2024 Category: Consumer Health News Source Type: news
I put my night sweats down to early menopause - it was actually late stage blood cancer
Susete Isabel, 40, of Toronto, Canada, was diagnosed with stage four follicular lymphoma after mistaking her symptoms for early menopause, drinking, and working too much. (Source: the Mail online | Health)
Source: the Mail online | Health - April 8, 2024 Category: Consumer Health News Source Type: news
PET/MRI detects brain injury in pediatric cancer survivors
PET/MRI could be a tool for diagnosing brain injury in young cancer survivors due to high-dose methotrexate treatment, according to pediatric radiologists at Stanford University in Stanford, CA.
In a pilot study in 10 children and young adults, F-18 FDG-PET/MRI detected brain injury based on reductions in glucose metabolism and blood flow in specific brain areas. The imaging findings could facilitate earlier treatments in these patients, noted lead author Lucia Baratto, MD, and colleagues.
“Using F-18 FDG-PET/MRI for assessing the cerebral impact of methotrexate therapy in pediatric cancer survivors holds the potential...
Source: AuntMinnie.com Headlines - April 8, 2024 Category: Radiology Authors: Will Morton Tags: Molecular Imaging Source Type: news
New study paves the way for precision drugs to treat blood cancers
The Janus kinase 2 (JAK2) protein mediates signaling from several cytokine receptors in the regulation of hematopoiesis and immune responses. Somatic mutations in human JAK2 lead to constitutive activation and cytokine-independent signaling and underlie several hematological malignancies from myeloproliferative neoplasms (MPN) to acute leukemia and lymphomas. JAK2 contains an active kinase domain and an inactive pseudokinase domain. Interestingly, pathogenic mutations mainly occur in the regulatory pseudokinase domain. (Source: World Pharma News)
Source: World Pharma News - April 4, 2024 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
Second Primary Malignancy Risk Increased After Cutaneous B-Cell Lymphoma
WEDNESDAY, April 3, 2024 -- Patients with primary cutaneous B-cell lymphomas (PCBCLs) have an increased risk for second primary malignancies (SPMs), according to a study published online March 19 in the Journal of the American Academy of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 3, 2024 Category: Pharmaceuticals Source Type: news
Johns Hopkins investigators develop novel treatment for T-cell leukemias and lymphomas
A novel treatment for leukemias and lymphomas that arise from immune system T cells, developed by investigators at the Johns Hopkins Kimmel Cancer Center and its Ludwig Center and Lustgarten Laboratory, was found to be effective at killing these cancers in mice bearing human T-cell tumors.
The therapy, an antibody-drug conjugate (ADC), combines an antibody that targets a protein called TRBC1 expressed on the surface of T-cell cancers with an anti-cancer drug, called SG3249. (Source: World Pharma News)
Source: World Pharma News - April 3, 2024 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
CAR T-Cell Therapy: What You Should Know Today
CAR T-cell therapy could be lifesaving if your leukemia or¬ lymphoma hasn’t responded to other treatments. Find out how this therapy works and what to expect. (Source: WebMD Health)
Source: WebMD Health - April 2, 2024 Category: Consumer Health News Source Type: news
CAR-T cell therapy helps man continue community advocacy
Sylvester Pinckney Sylvester Pinckney is someone who knows a lot about teamwork. He was a star football player in high school and college; he and his wife, Sabrina, have raised a family together; and for more than 20 years, he has worked to promote the well-being of children throughout his community. When Sylvester was diagnosed with follicular lymphoma in 2016, he knew he would have a team supporting him. "When you have the opportunity to… (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - April 2, 2024 Category: Databases & Libraries Source Type: news
BusinessWoman of the Year 2024: Rebecca Siviglia of H. Lee Moffitt Cancer Center and Research Institute
Siviglia serves in leadership at the American Cancer Society, the Leukemia and Lymphoma Society, and the Tampa Bay Chamber of Commerce. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - March 29, 2024 Category: Biotechnology Authors: Brooke Strickland Source Type: news
PD-1 Inhibitor Plus Chemotherapy Shows Promising Activity in Rare Lymphoma
(MedPage Today) -- An investigational PD-1 inhibitor combined with chemotherapy showed impressive activity in treatment-naive patients with advanced extranodal natural killer/T-cell lymphoma (ENKTL), according to results from a small Chinese single... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - March 28, 2024 Category: Hematology Source Type: news
Kate Middleton Had to Tell Her Kids About Her Cancer Diagnosis. These Parents Know What That ’ s Like
After weeks of fevered speculation, Catherine, Princess of Wales, revealed on Mar. 22 that she was absent from the public eye not because she was having marital problems or growing out a bad haircut, but because she was being treated for cancer. She and her husband had, she said, “taken time to explain everything to George, Charlotte and Louis in a way that is appropriate for them, and to reassure them that I am going to be OK.” Even before her announcement, however, many cancer survivors who were also parents had already guessed at the truth. The silence and delay tactics looked familiar, because they had done...
Source: TIME: Health - March 28, 2024 Category: Consumer Health News Authors: Belinda Luscombe Tags: Uncategorized Cancer Source Type: news
Regeneron's Blood Cancer Therapy Faces Setback as FDA Raises Trial Concerns Regeneron's Blood Cancer Therapy Faces Setback as FDA Raises Trial Concerns
Regeneron Pharmaceuticals said on Monday the U.S. FDA has declined approval for its blood cancer therapy for two forms of lymphoma, raising concerns over the progress of...Reuters Health Information (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - March 25, 2024 Category: Internal Medicine Tags: Hematology-Oncology Source Type: news
How to survive cancer, from the man who has beaten the disease five times
Bill Potts from Florida has survived cancer five times: thyroid cancer once and non-Hodgkin lymphoma four times. 'It sounds odd to even say those words. It's such a big number,' he said. (Source: the Mail online | Health)
Source: the Mail online | Health - March 24, 2024 Category: Consumer Health News Source Type: news
